Alumis Inc. Common Stock (ALMS)
7.67
0.03 (0.39%)
At close: Jan 15, 2025, 10:35 AM
undefined% (undefined)
| Bid | 7.66 |
| Market Cap | 417.30M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.39 |
| PE Ratio (ttm) | -1.75 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 7.82 |
| Volume | 8,806 |
| Avg. Volume (20D) | 114,454 |
| Open | 7.70 |
| Previous Close | 7.64 |
| Day's Range | 7.38 - 7.71 |
| 52-Week Range | 6.75 - 13.53 |
| Beta | undefined |
About ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 22, 2021
Employees 107
Stock Exchange NASDAQ
Ticker Symbol ALMS
Website https://www.alumis.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ALMS stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 278.10% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
-12.95%
Alumis shares are trading lower after HC Wainwrigh...
Unlock content with
Pro Subscription
3 months ago ·
Source
-6.77%
Alumis shares are trading lower. The company presented the 28-week open label extension period data from its Phase 2 STRIDE trial of ESK-001.
